About Us



Page 11234..1020..»




Alimera Sciences Reports Fourth Quarter and 2020 Results

Posted: February 25, 2021 at 6:44 am


Fourth Quarter Highlights:

More here:
Alimera Sciences Reports Fourth Quarter and 2020 Results

GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

Posted: at 6:44 am


Achieved Oxbryta® (voxelotor) net revenues of $41.3 million in the fourth quarter and $123.8 million for full year 2020

The rest is here:
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event

Posted: at 6:44 am


Acquires Tetramer Shop; Reveals Details on Upcoming Products Acquires Tetramer Shop; Reveals Details on Upcoming Products

See the article here:
10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event

Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference

Posted: at 6:44 am


JERSEY, Channel Islands, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the Company will present at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 1:20pm ET.

Read more:
Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference

Seer to Present at the Cowen 41st Annual Healthcare Conference

Posted: at 6:44 am


REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating in the upcoming Cowen 41st Annual Healthcare Conference.

Originally posted here:
Seer to Present at the Cowen 41st Annual Healthcare Conference

Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy

Posted: at 6:44 am


- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector -

Read the original:
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy

CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Posted: at 6:44 am


-Broad advancement of clinical pipeline-

Link:
CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

ERYTECH to Participate in Upcoming Virtual Investor Conferences in March

Posted: at 6:44 am


ERYTECH to Participate in Upcoming Virtual Investor Conferences in March

Read more:
ERYTECH to Participate in Upcoming Virtual Investor Conferences in March

vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Posted: at 6:44 am


Initiation of Mechanistic Study of TTP399 expected during Q1 2021

See the original post:
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Antares Pharma to Present at Two Upcoming Investor Conferences

Posted: at 6:44 am


EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to present and host investor meetings at the Raymond James 42nd Annual Virtual Institutional Investors Conference and the Cowen 41st Annual Virtual Healthcare Conference.

Continue reading here:
Antares Pharma to Present at Two Upcoming Investor Conferences

Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of…

Posted: at 6:44 am


Basel, 25 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine has published Evrysdi™ (risdiplam) data from the dose finding Part 1 of the pivotal FIREFISH study in infants with symptomatic Type 1 spinal muscular atrophy (SMA). The data show that treatment with Evrysdi at 12 months helped 90% (19/21) of these infants survive without permanent ventilation and 33% (7/21) sit without support for at least 5 seconds, which is not normally seen in the natural course of the disease. The study also found that treatment with Evrysdi increased the levels of survival of motor neuron (SMN) protein by a median 1.9-fold from baseline in the high-dose cohort at 12 months.

Original post:
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of...

Valneva Reports FY 2020 Results and Major Corporate Achievements

Posted: at 6:44 am


Thomas Lingelbach, Chief Executive Officer, commented, “2020 was a transformational year for Valneva, marked by major partnerships with Pfizer and the UK government as well as substantial progress across all of our clinical programs. Our company has responded very well to the challenges presented to us by the COVID pandemic. With over €200 million of cash, Valneva is in a strong position to continue to focus on execution of our key programs which could result in even greater transformation in 2021 and beyond.”

Read more:
Valneva Reports FY 2020 Results and Major Corporate Achievements

argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021

Posted: at 6:44 am


February 25, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update.

Continue reading here:
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021

Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Posted: at 6:44 am


Positive Phase 2 results with pMDI ensifentrine in COPD

Original post:
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

LIDDS and Pharmidea signs manufacturing agreement

Posted: at 6:44 am


UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a collaboration agreement has been signed with the R&D and Production company PharmIdea SIA in Riga, Latvia. PharmIdea focuses on anti-cancer drugs and sterile formulations. The collaboration enables LIDDS to expand the manufacturing of new product candidates, e.g. including biomolecules and cytostatics, in addition to the already existing collaboration with Recipharm for Liproca Depot.

Read the rest here:
LIDDS and Pharmidea signs manufacturing agreement

DEBx Medical Receives CE Mark Clearance and ISO 13485 Certification for Debrichem®, a Novel Desiccant Gel for Chemical Debridement to Initiate…

Posted: at 6:44 am


ROTTERDAM, The Netherlands, Feb. 25, 2021 (GLOBE NEWSWIRE) -- DEBx Medical, the Dutch medical technology company revolutionizing the management of chronic wounds, is excited to highlight today the successful completion of the CE conformity assessment procedure for Debrichem®. The innovative topical agent offers a superior alternative to surgical debridement, the current standard of care. Debrichem can now carry the CE mark for a medical device class IIb and has also been awarded ISO 13485:2016 certification. These certifications endorse the quality and safety of Debrichem to treat a high unmet medical need and the strength of the DEBx Medical team to achieve this quickly even in such difficult times. DEBx Medical plans first to launch Debrichem in Europe, South Africa as well as Hong Kong, New Zealand and Australia through a network of distribution partners; other markets will follow. DEBx Medical has started consultations with the FDA about the pathway to approval earlier this year.

See the original post:
DEBx Medical Receives CE Mark Clearance and ISO 13485 Certification for Debrichem®, a Novel Desiccant Gel for Chemical Debridement to Initiate...

LIDDS Interim report January – December 2020

Posted: at 6:44 am


JANUARY – DECEMBER 2020

The rest is here:
LIDDS Interim report January – December 2020

Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Posted: at 6:44 am


Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact

Follow this link:
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

Posted: at 6:44 am


- Commenced enrollment in both the Phase 1 INNATE trial of JTX-8064 (LILRB2 / ILT4) and the Phase 2 SELECT trial of Vopratelimab in combination with JTX-4014 -

Read the original here:
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update

Posted: at 6:44 am


- Interim Data Reported from First 20 Adult Patients Enrolled with January 22, 2021 Data Cutoff -

Originally posted here:
SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update

Next Posts »



Page 11234..1020..»